1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Slovakia Pharmaceuticals and Healthcare Report Q4 2015

Slovakia Pharmaceuticals and Healthcare Report Q4 2015

  • September 2015
  • -
  • Business Monitor International
  • -
  • 116 pages

Includes 3 FREE quarterly updates

BMI’s commercial banking forecast series covers 62 countries accounting for 80% of global GDP. Each report, researched at source, features BMI’s independent assessment and 5-year forecasts to end-2017 for the commercial banking sector in each market. Using its expertise in both country risk and financial markets analysis, BMI has created exclusive models to forecast a wealth of key variables on the commercial banking sector. Historic and forecast data are provided for the sector’s total asset and liability growth, client loans, and client deposits. Forecasts for key ratios including the loan-deposit ratio and the loan-asset ratio are also included, as well as core macro-economic forecasts.

Data is presented in both local currency and US dollar terms.Each report examines key drivers of growth and future prospects, including the macroeconomic situation, the level of development and potential for growth of the banking sector, the commercial initiatives of major players, government policy and the regulatory environment. Central to BMI’s analysis are our unique Commercial Banking Business Environment Ratings. BMI’s unique country-comparative Risk-Reward Rating provides a clear, quantified, independent assessment of the opportunities and dangers of operating in each market.

The methodology draws together our in-depth knowledge of competitive pressures, our comprehensive industry market forecasts, and our Country Risk team’s unrivalled analysis of economic, political and operational risks.The reports also feature profiles of leading banks, covering total assets, liabilities, client deposits, lending, bond holdings, main products and services, competitive positioning and ownership structure.

Table Of Contents

Slovakia Pharmaceuticals and Healthcare Report Q4 2015
BMI Industry View 7
SWOT 9
Politics 11
Economic 12
Operational Risk 13
Industry Forecast 15
Pharmaceutical Market Forecast 15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Slovakia 2011-2019) 16
Healthcare Market Forecast 17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2011-2019) 19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2011-2019) 19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2011-2019) 20
Prescription Drug Market Forecast 21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Slovakia 2011-2019) 23
Patented Drug Market Forecast 24
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Slovakia 2011-2019) 25
Generic Drug Market Forecast 26
Table: Members Of GENAS, 2015 28
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Slovakia 2011-2019) 28
OTC Drug Market Forecast 29
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Slovakia 2011-2019) 31
Pharmaceutical Trade Forecast 32
Table: Pharmaceutical Trade Data And Forecasts (Slovakia 2013-2019) 34
Table: Pharmaceutical Trade Data And Forecasts local currency (Slovakia 2013-2019) 34
Key Risks To BMI's Forecast Scenario 35
Macroeconomic Forecasts 36
Economic Analysis 36
Table: Slovakia - Private Consumption Forecasts 41
Table: Slovakia - Public Consumption Forecasts 41
Table: Slovakia - Fixed Investment Forecast 42
Table: Slovakia - Net Export Forecasts 42
Industry Risk Reward Indices 43
Central And Eastern Europe Risk/Reward Index - Q4 2015 43
Slovakia Risk/Reward Index 49
Rewards 49
Risks 49
Market Overview 51
Industry Trends And Developments 53
Epidemiology 53
Table: Main Causes Of Mortality And Morbidity In Slovakia 54
Communicable Diseases 54
Healthcare Sector 55
Table: Healthcare Resources (Slovakia 2009-2014) 56
Table: Healthcare Personnel (Slovakia 2009-2014) 57
Table: Healthcare Activity (Slovakia 2009-2014) 57
Health Insurance 58
Private Health Insurance 59
Recent Health Insurance Developments 60
Research And Development 62
Table: Members Of BITCET, 2011 63
Table: Members Of SLOVBIOTECH, 2010 64
Clinical Trials 64
Regulatory Development 66
Regulatory Regime 66
Pharmaceutical Promotion And Advertising 67
Marketing Authorisation Regime 68
Intellectual Property Issues 69
Pricing Regime 70
Table: Indexed Price Build-Up For Prescription And Non-Prescription Medicines In Slovakia 71
Reimbursement Regime 72
Competitive Landscape 77
Research-Based Industry 77
Table: Members Of SAFS, 2012 77
Generic Drugmakers 77
Table: Registered Pharmaceutical Manufacturers 78
Pharmaceutical Distribution 79
Table: ADL Members, 2012 (Manufacturers, unless otherwise indicated) 80
Pharmaceutical Retail Sector 80
Company Profile 83
Roche 83
Biotika 85
HBM Pharma 87
Imuna Pharma 90
GlaxoSmithKline 92
Sanofi 94
Pfizer 96
Novartis 98
Merck and Co 100
Zentiva (Sanofi) 102
Demographic Forecast 105
Table: Population Headline Indicators (Slovakia 1990-2025) 106
Table: Key Population Ratios (Slovakia 1990-2025) 106
Table: Urban/Rural Population and Life Expectancy (Slovakia 1990-2025) 107
Table: Population By Age Group (Slovakia 1990-2025) 107
Table: Population By Age Group % (Slovakia 1990-2025) 108
Glossary 110
Methodology 112
Pharmaceutical Expenditure Forecast Model 112
Healthcare Expenditure Forecast Model 112
Notes On Methodology 113
Risk/Reward Index Methodology 114
Index Overview 115
Table: Pharmaceutical Risk/Reward Index Indicators 115
Indicator Weightings 116

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.